Brand Reference: Protopic
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tacrolimus 0.1% Topical Ointment RxNorm Concept ID | 42316 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $162.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $29.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $33.00 / mo | 17 Zero-PHI Verified Patient Logs |
Complexes with keratinocyte and Langerhans-cell FKBP12 to inhibit calcineurin phosphatase, blocking nuclear translocation of NFAT and T-cell IL-2/IL-4 cytokine transcription—clearing facial, eyelid, and intertriginous dermatitis with zero corticosteroid collagen atrophy.
For self-pay patients filling Tacrolimus 0.1% Topical Ointment (NDC 00469-5301-30), direct wholesale and telehealth fulfillment drops monthly spend from $162.00 retail to $29.80 (82% savings against a $1.1200 CMS pharmacy acquisition baseline).
Clinical clearance of Tacrolimus 0.1% Topical Ointment (Non-Steroidal Macrolide Calcineurin / NFAT T-Cell Inhibitor) relies on trace hepatic cyp3a4 if absorbed across eroded skin with a Local dermal persistence; minimal blood clearance needed half-life; patients absorbing at < 0.5 ng/mL systemic across intact barrier bioavailability typically observe target onset around 3–7 days pruritus and erythema resolution.
FDA clinical labeling for Tacrolimus 0.1% Topical Ointment restricts administration in netherton syndrome (severe barrier defect absorption); active cutaneous hsv/vzv infection across 0.03% ointment BID, 0.1% ointment thin film BID until clear, then twice-weekly proactive maintenance, with self-reported patient tracking dominated by transient warm burning sensation (days 1–4) (36% of reports), alcohol facial flush reaction (15% of reports).
Across 17 verified cash-pay logs, Tacrolimus 0.1% Topical Ointment achieves a 90.40% Worth-It rating with out-of-pocket spend averaging $33.00/mo versus $162.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.03% ointment BID for Tacrolimus 0.1% Topical Ointment; monthly out-of-pocket dropped to $26.22 compared with $162.00 retail.
Completed 10 weeks on Tacrolimus 0.1% Topical Ointment (0.1% ointment thin film BID until clear, then twice-weekly proactive maintenance). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.03% ointment BID Tacrolimus 0.1% Topical Ointment sourced via Cost Plus Drugs ($34.57/mo cash pay without insurance prior authorization).